ALX Oncology Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing immuno-oncology therapies that enhance the immune system's ability to combat cancer. Its primary mission centers on advancing innovative treatments to improve patient outcomes in oncology. The company's lead candidate, evorpacept, represents a key asset designed to synergize with existing therapies, potentially optimizing standards of care in immuno-oncology. ALX Oncology Holdings Inc. employs a differentiated scientific approach targeting immune modulation to address unmet needs across various cancer types. This positions it within the competitive biotechnology sector, contributing to the evolution of cancer treatment paradigms through rigorous clinical development. Headquartered in South San Francisco, California, the company is driven by an experienced leadership team dedicated to oncology innovation. By harnessing the power of the immune system, ALX Oncology Holdings Inc. plays a vital role in the broader effort to deliver next-generation therapies for cancer patients.